Get the Stockscreener App
55.58
1.87%
1.02
After Hours:
55.58
Supernus Pharmaceuticals Inc stock is traded at $55.58, with a volume of 532.77K.
It is up +1.87% in the last 24 hours and up +13.24% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$54.56
Open:
$54.72
24h Volume:
532.77K
Relative Volume:
0.74
Market Cap:
$3.19B
Revenue:
$665.13M
Net Income/Loss:
$64.50M
P/E Ratio:
48.58
EPS:
1.1442
Net Cash Flow:
$185.87M
1W Performance:
-1.31%
1M Performance:
+13.24%
6M Performance:
+22.34%
1Y Performance:
+75.61%
1-Day Range:
$54.16
$56.49
1-Week Range:
$52.95
$56.59
52-Week Range:
$29.16
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
55.58 | 3.13B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.98 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Supernus (NASDAQ: SUPN) CFO receives performance share unit grant - Stock Titan
Supernus Pharmaceuticals (SUPN) CEO awarded 38,640 performance units - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP gets 3,750 performance share units - Stock Titan
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One-Year Surge? - simplywall.st
Supernus Pharmaceuticals (SUPN) Stock Analysis: A 14.66% Upside and Strong Buy Ratings Shape Investor Outlook - DirectorsTalk Interviews
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One Year Rally? - Yahoo Finance
Envestnet Asset Management Inc. Sells 63,513 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Supernus at TD Cowen Conference: Strategic Diversification Unveiled By Investing.com - Investing.com South Africa
Supernus at TD Cowen Conference: Strategic Diversification Unveiled - Investing.com
Supernus Pharmaceuticals (SUPN) Releases Q4 2025 Earnings: Revenue Up, Operating and Net Losses - Quiver Quantitative
Supernus Pharmaceuticals 2025 10-K: $718.95M Revenue, $(0.68) EPS - TradingView
Sage acquisition and ZURZUVAE strategy reshape Supernus (NASDAQ: SUPN) - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook - simplywall.st
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Vanguard Group Inc. - MarketBeat
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
Supernus (SUPN) SVP reports RSU vesting and tax-withholding share disposition - Stock Titan
Supernus (NASDAQ: SUPN) CFO reports RSU vesting and tax share withholding - Stock Titan
SUPERNUS (NASDAQ: SUPN) executive logs RSU grant and tax share withholding - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals stock hits 52-week high at $57.76 By Investing.com - Investing.com Australia
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Director in Supernus (NASDAQ: SUPN) gets 4,475-share stock award - Stock Titan
TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch - Investing.com Nigeria
Supernus Pharmaceuticals stock hits 52-week high at $57.76 - Investing.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month HighTime to Buy? - MarketBeat
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains - Investing.com Nigeria
Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains By Investing.com - Investing.com UK
Supernus FY25 Total Revenues Up 9%; Guides 17-21% Growth For FY26 - RTTNews
Earnings Call Summary | Supernus Pharmaceuticals(SUPN.US) Q4 2025 Earnings Conference - 富途牛牛
Supernus Pharmaceuticals Swings to Q4 Loss, Revenue Rises - marketscreener.com
Supernus Pharmaceuticals (SUPN) Returns To Quarterly EPS Loss Reinforcing Profitability Concerns - Sahm
Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook Highlights 21% Potential Upside - DirectorsTalk Interviews
Supernus Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highli - GuruFocus
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Millennium Management LLC Increases Stake in Supernus Pharmaceuticals Inc. - GuruFocus
Supernus Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SUPN Sets 2026 Revenue and Earnings Guidance - GuruFocus
Supernus (SUPN) Reports Strong Q4 Revenue and Outlines Future Pl - GuruFocus
Supernus: Fourth Quarter Financial Overview - Bitget
Supernus: Q4 Earnings Snapshot - marketscreener.com
Supernus boosts executive pay with new equity incentives - TipRanks
Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Misses Expectations By $0.48 EPS - MarketBeat
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales - TradingView
Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q4 Revenue $211.6M, vs. FactSet Est of $195.2M - marketscreener.com
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sensenig Bethany | Director |
Feb 19 '26 |
Option Exercise |
0.00 |
4,475 |
0 |
4,475 |
| Sensenig Bethany | Director |
Feb 19 '26 |
Sale |
51.01 |
4,475 |
228,265 |
0 |
0.18%
1.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):